

Determinants of Adherence to Glaucoma Medical Thera

Journal of Glaucoma

18, 238-243

DOI: [10.1097/ijg.0b013e3181815421](https://doi.org/10.1097/ijg.0b013e3181815421)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Improving care of chronic open angle glaucoma. Nursing Older People, 2010, 22, 18-23.	0.2	4
3	Evaluation of Factors Affecting the Compliance and Treatment Adherence in Glaucoma Patients. Türk Oftalmoloji Dergisi, 2010, 40, 199-204.	0.9	0
5	Glaucoma among patients enrolled in a national vision care plan. Optometry - Journal of the American Optometric Association, 2010, 81, 663-670.	0.6	2
7	Ocular Hypotensive Effects and Safety over 3 Months of Switching from an Unfixed Combination to Latanoprost 0.005%/Timolol Maleate 0.5% Fixed Combination. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 581-587.	1.4	16
8	Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Current Medical Research and Opinion, 2011, 27, 1949-1958.	1.9	29
9	Drops, Drops, and More Drops. , 0, , .		2
10	Adherence to Topical Glaucoma Medication During Hospitalization. Journal of Glaucoma, 2011, 20, 573-576.	1.6	9
11	Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Preference and Adherence, 2011, 5, 441.	1.8	127
12	Role of fixed combinations in the management of open-angle glaucoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 91-99.	1.4	14
14	Intraocular Pressure-Lowering Effect of 0.005% Latanoprost with Two Different Dosing Regimens. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 524-528.	1.4	1
15	Determinants of Medication Adherence to Topical Glaucoma Therapy. Journal of Glaucoma, 2012, 21, 234-240.	1.6	117
16	A 2-hour Information Session and Patient Recall has Minimal Impact on Glaucoma-treatment Persistence in a Mature Practice. Journal of Glaucoma, 2012, 21, 379-382.	1.6	8
17	Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Japanese Journal of Ophthalmology, 2012, 56, 559-563.	1.9	18
18	Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up. Journal of Cataract and Refractive Surgery, 2012, 38, 1339-1345.	1.5	283
19	Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues. Drugs, 2012, 72, 1355-1371.	10.9	25
20	Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial. Clinical Ophthalmology, 2012, 6, 369.	1.8	8
21	Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clinical Ophthalmology, 2012, 6, 771.	1.8	13
22	Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs. Clinical Ophthalmology, 2012, 6, 231.	1.8	10

#	ARTICLE	IF	CITATIONS
23	Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy. Japanese Journal of Ophthalmology, 2012, 56, 339-345.	1.9	11
24	Development and Validation of a Predictive Model for Nonadherence with Once-Daily Glaucoma Medications. Ophthalmology, 2013, 120, 1396-1402.	5.2	40
25	Development of Latanoprost-Loaded Biodegradable Nanosheet as a New Drug Delivery System for Glaucoma. , 2013, 54, 5629.		24
26	Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology, 2013, 8, 149.	1.8	1
27	Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Preference and Adherence, 2014, 8, 853.	1.8	17
28	Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology, 2014, 8, 219.	1.8	7
29	Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology, 2014, 8, 389.	1.8	2
30	Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy. Clinical Ophthalmology, 2014, 8, 1527.	1.8	2
31	Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months. Clinical Ophthalmology, 2014, 8, 1275.	1.8	2
32	Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opinion on Pharmacotherapy, 2014, 15, 1737-1747.	1.8	85
33	Comparison of Corneal Safety and Intraocular Pressure"Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 340-345.	1.4	8
34	Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis. The Cochrane Library, 2014, 2014, .	2.8	5
35	Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opinion on Pharmacotherapy, 2014, 15, 2255-2262.	1.8	11
36	Efficacy and Tolerability of Fixed-Combination Brinzolamide/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination. Advances in Therapy, 2014, 31, 975-985.	2.9	4
37	Electronic Monitoring to Assess Adherence With Once-Daily Glaucoma Medications and Risk Factors for Nonadherence. JAMA Ophthalmology, 2014, 132, 838.	2.5	62
38	Twice-Daily Brinzolamide/Brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology, 2014, 121, 2348-2355.	5.2	44
39	Examining Patient Provider Communication Regarding Cost In The Glaucoma Patient Population. Value in Health, 2014, 17, A287.	0.3	1
40	Glaucoma Patient Expression of Medication Problems and Nonadherence. Optometry and Vision Science, 2015, 92, 537-543.	1.2	19

#	ARTICLE	IF	CITATIONS
41	Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F ₂ α analog. <i>Clinical Ophthalmology</i> , 2015, 9, 475.	1.8	2
42	Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. <i>Clinical Ophthalmology</i> , 2015, 9, 2263.	1.8	2
43	Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. <i>Clinical Ophthalmology</i> , 2015, 9, 2201.	1.8	20
44	Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops. <i>Clinical Ophthalmology</i> , 2015, 9, 619.	1.8	3
45	Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-7.	1.3	8
46	Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors. <i>Clinical Therapeutics</i> , 2015, 37, 1975-1985.	2.5	36
47	Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial. <i>Ophthalmic Epidemiology</i> , 2015, 22, 380-386.	1.7	17
48	Predictors of Adherence to Glaucoma Treatment in a Multisite Study. <i>Annals of Behavioral Medicine</i> , 2015, 49, 29-39.	2.9	29
49	Adherence to topical glaucoma medications in Ethiopian patients. <i>Middle East African Journal of Ophthalmology</i> , 2015, 22, 59.	0.3	39
50	The Relationship Between Sociodemographic Factors and Persistence With Topical Glaucoma Medications. <i>Journal of Glaucoma</i> , 2015, 24, 69-76.	1.6	28
51	Dry eye specific quality of life in veterans using glaucoma drops. <i>Contact Lens and Anterior Eye</i> , 2015, 38, 220-225.	1.7	27
52	Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study. <i>Advances in Therapy</i> , 2015, 32, 823-837.	2.9	10
53	Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 518-524.	1.4	3
54	Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient population. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1931-1937.	1.8	28
55	Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 808-817.	0.9	16
56	Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue. <i>Clinical Ophthalmology</i> , 2016, Volume 11, 55-61.	1.8	0
57	Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-22.	1.3	70
58	Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. <i>PLoS ONE</i> , 2016, 11, e0158797.	2.5	7

#	ARTICLE	IF	CITATIONS
59	Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2016, 10, 583.	1.8	7
60	Systematic review of educational interventions to improve glaucoma medication adherence: an update in 2015. <i>Expert Review of Ophthalmology</i> , 2016, 11, 5-20.	0.6	29
62	Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety. <i>Ophthalmology and Therapy</i> , 2016, 5, 191-206.	2.3	14
64	Effect of Switching From Latanoprost to Bimatoprost in Primary Open-Angle Glaucoma Patients Who Experienced Intraocular Pressure Elevation During Treatment. <i>Journal of Glaucoma</i> , 2016, 25, e359-e366.	1.6	5
65	Use of Ocular Hypotensive Medications in Portugal: PEM Study: A Cross-sectional Nationwide Analysis. <i>Journal of Glaucoma</i> , 2017, 26, 571-576.	1.6	13
66	Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. <i>American Journal of Ophthalmology</i> , 2017, 176, 61-69.	3.3	40
68	Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-6.	1.3	14
69	Glaucoma Adherence—From Theriac to the Future. <i>American Journal of Ophthalmology</i> , 2018, 191, xiii-xv.	3.3	6
70	Adherencia al tratamiento t3pico del glaucoma, factores protectores y de riesgo; una revisi3n del tema. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2018, 93, 87-92.	0.2	14
71	Adherence to topical treatment of glaucoma, risk and protective factors: A review. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2018, 93, 87-92.	0.2	10
72	Multiple deprivation, vision loss, and ophthalmic disease in adults: global perspectives. <i>Survey of Ophthalmology</i> , 2018, 63, 406-436.	4.0	30
73	Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1567-1577.	1.8	7
74	Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-9.	1.3	1
75	Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 531-537.	1.4	72
76	Medication adherence in patients with ocular hypertension or glaucoma. <i>Expert Review of Ophthalmology</i> , 2019, 14, 199-210.	0.6	31
77	Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol. <i>Scientific Reports</i> , 2019, 9, 7491.	3.3	11
78	A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. <i>International Ophthalmology</i> , 2019, 39, 375-383.	1.4	14
79	<p></p>Level of Glaucoma Drug Adherence and Its Associated Factors Among Adult Glaucoma Patients Attending Felege Hiwot Specialized Hospital, Bahir Dar City, Northwest Ethiopia<p></p>. <i>Clinical Optometry</i> , 2020, Volume 12, 189-197.	1.2	8

#	ARTICLE	IF	CITATIONS
80	Adherence to Topical Medication in Patients with Inflammatory Eye Disease. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 890-895.	1.8	6
81	Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials. <i>American Journal of Ophthalmology</i> , 2020, 216, 110-120.	3.3	10
82	Assessment of medication therapy adherence in glaucoma: scoping review. <i>Expert Review of Ophthalmology</i> , 2021, 16, 113-124.	0.6	0
83	Bypassing the Trabecular Meshwork: Worth It or Not?. <i>Ophthalmology Glaucoma</i> , 2021, 4, 115-116.	1.9	1
84	Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma. <i>Journal of Drug Assessment</i> , 2021, 10, 91-96.	2.2	3
85	Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma. <i>Open Ophthalmology Journal</i> , 2018, 12, 121-126.	0.2	2
86	Adherence and Persistence with Glaucoma Therapy: Brimonidine/Timolol versus Dorzolamide/Timolol and Various Two-Bottle Combinations. <i>Journal of Clinical & Experimental Ophthalmology</i> , 2012, 03, .	0.1	10
87	Tolerancia y Efectividad de los Análogos de Prostaglandinas en Pacientes Glaucomatosos. <i>Highlights of Ophthalmology</i> , 2013, 41, 22-26.	0.0	0
88	Tolerance and Effectivity of Prostaglandin Analogues in Glaucoma Patients. <i>Highlights of Ophthalmology</i> , 2013, 41, 19-22.	0.0	0
90	Switching Study of Tafluprost/Timolol Fixed-Combination Ophthalmic Solution, Following Unfixed Combination of Tafluprost Ophthalmic Solution 0.0015% and Timolol Ophthalmic Gel-Forming Solution 0.5%. <i>Open Journal of Ophthalmology</i> , 2019, 09, 168-182.	0.3	0
91	Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part II. <i>Oftalmologiya</i> , 2020, 17, 676-682.	0.5	2
92	The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 5228.	2.4	3
93	Surgical Outcomes of a Small Incision Limbus-Based Revision for Failed Trabeculectomies. <i>Open Journal of Ophthalmology</i> , 2022, 12, 121-127.	0.3	0
94	Frequency of Use of Fixed-Combination Eye Drops by Patients with Glaucoma at Multiple Private Practices in Japan. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 557-565.	1.8	1
95	Intraocular Peak Pressure in Patients under Treatment with Fixed Combination of Bimatoprost/Timolol/ Brimonidine once Daily versus Twice Daily. <i>Journal of Glaucoma</i> , 2022, Publish Ahead of Print, .	1.6	0
96	Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2167.	0.9	0
97	Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications. <i>Japanese Journal of Ophthalmology</i> , 2022, 66, 440-446.	1.9	4
98	The IOP lowering effects of selective laser trabeculoplasty in open angle glaucoma. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0

#	ARTICLE	IF	CITATIONS
99	Compliance with Medical Treatment in Primary Open-Angle Glaucoma (POAG) at the Centre for the Application of the Diploma of Specialized Studies in Ophthalmology (CADES/O). <i>Open Journal of Ophthalmology</i> , 2022, 12, 382-391.	0.3	0
100	Evaluation of Medication Adherence of Glaucoma Patients During the Covid-19 Pandemic. <i>Journal Francais D'Ophthalmologie</i> , 2022, , .	0.4	0
101	The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 2057.	2.5	2
102	Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients. <i>BMJ Open Ophthalmology</i> , 2022, 7, e001200.	1.6	2
103	The Japan Glaucoma Society guidelines for glaucoma 5th edition. <i>Japanese Journal of Ophthalmology</i> , 2023, 67, 189-254.	1.9	17
104	Eye Drop Adherence with an Eye Drop Bottle Cap Monitor. <i>Journal of Glaucoma</i> , 0, Publish Ahead of Print, .	1.6	0
106	Disparities in Eye Care Access and Utilization: A Narrative Review. <i>Annual Review of Vision Science</i> , 2023, 9, .	4.4	0
107	Evaluation of antiglaucoma drug treatment awareness and patient-reported medication adherence: Determinants of glaucoma management. <i>Journal of Postgraduate Medicine</i> , 2023, 69, 146-152.	0.4	1
108	Highlighting the Issues Associated with Glaucoma Medication Therapy: A Pharmaceutical Care Evaluation. <i>Al-Rafidain Journal of Medical Sciences</i> , 0, 5, 57-66.	0.0	0
109	Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma. <i>Journal of Glaucoma</i> , 2023, 32, 738-743.	1.6	1
110	Efficiency and safety of the fixed latanoprost/ dorzolamide combination in open-angle glaucoma hypotensive treatment. <i>Rossiiskii Oftal'mologicheskii Zhurnal</i> , 2023, 16, 60-68.	0.4	0
111	Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework. <i>Ophthalmic and Physiological Optics</i> , 2024, 44, 96-114.	2.0	1
112	Switching to Brimonidine/Ripasudil Fixed Combination from Brimonidine + Ripasudil. <i>Clinical Ophthalmology</i> , 0, Volume 18, 423-430.	1.8	1
113	Social determinants of health and health disparities in glaucoma: A review. <i>Clinical and Experimental Ophthalmology</i> , 2024, 52, 276-293.	2.6	0